{"database":"biostudies-literature","file_versions":[],"scores":null,"additional":{"omics_type":["Unknown"],"volume":["13(11)"],"submitter":["Dolat M"],"pubmed_abstract":["In order to limit 5-fluorouracil (5-FU) toxicity, some health agencies recommend evaluating dihydropyrimidine dehydrogenase (DPD) deficiency before any 5-FU treatment introduction. In our study, we investigated relationships between 5-FU clearance and markers of DPD activity such as uracilemia (U), dihydrouracilemia (UH2)/U ratio, or genotype of the gene encoding DPD (DPYD). All patients with gastrointestinal cancers who received 5-FU-based regimens form March 2018 to June 2020 were included in our study. They routinely benefited of a pre-therapeutic DPYD genotyping and phenotyping. During 5-FU infusion, blood samples were collected to measure 5-FU steady-state concentration in order to adapt 5-FU doses at the following cycles. A total of 169 patients were included. Median age was 68 (40-8"],"journal":["Pharmaceuticals (Basel, Switzerland)"],"pagination":["E416"],"full_dataset_link":["https://www.ebi.ac.uk/biostudies/studies/S-EPMC7700344"],"repository":["biostudies-literature"],"pubmed_title":["Association of 5-FU Therapeutic Drug Monitoring to DPD Phenotype Assessment May Reduce 5-FU Under-Exposure."],"pmcid":["PMC7700344"],"pubmed_authors":["Dolat M","Goirand F","Ghiringhelli F","Vincent J","Macaire P","Bengrine-Lefevre L","Royer B","Palmier R","Hennequin A","Schmitt A"],"additional_accession":[]},"is_claimable":false,"name":"Association of 5-FU Therapeutic Drug Monitoring to DPD Phenotype Assessment May Reduce 5-FU Under-Exposure.","description":"In order to limit 5-fluorouracil (5-FU) toxicity, some health agencies recommend evaluating dihydropyrimidine dehydrogenase (DPD) deficiency before any 5-FU treatment introduction. In our study, we investigated relationships between 5-FU clearance and markers of DPD activity such as uracilemia (U), dihydrouracilemia (UH2)/U ratio, or genotype of the gene encoding DPD (DPYD). All patients with gastrointestinal cancers who received 5-FU-based regimens form March 2018 to June 2020 were included in our study. They routinely benefited of a pre-therapeutic DPYD genotyping and phenotyping. During 5-FU infusion, blood samples were collected to measure 5-FU steady-state concentration in order to adapt 5-FU doses at the following cycles. A total of 169 patients were included. Median age was 68 (40-8","dates":{"release":"2020-01-01T00:00:00Z","publication":"2020 Nov","modification":"2025-04-04T22:36:52.647Z","creation":"2021-02-20T03:07:30Z"},"accession":"S-EPMC7700344","cross_references":{"pubmed":["33238487"],"doi":["10.3390/ph13110416"]}}